Skip to content ↓

Search committee named to identify new OSP head

Financial Operations Vice President James J. Culliton has appointed a search committee to recommend a successor to George H. Dummer, director of the MIT Office of Sponsored Programs since 1971. Mr. Dummer has indicated his desire to step down from that position.

Mr. Dummer said he believes it is time for new leadership in the management of the OSP. After his successor is identified, he will devote his efforts to the problems and challenges being created by the changing research environment.

The search committee is headed by Professor Kim Vandiver of the Department of Ocean Engineering. Other members are Professor Jonathan Allen, director of the Research Laboratory of Electronics; Jean Dzengeleski, special project director, Office of the Provost; Kenneth L. Hewitt, MIT senior personnel officer; Philip J. Keohan, comptroller of MIT; Professor Monty Krieger of the Department of Biology; Albert Vezza, senior research scientist and associate director, Laboratory for Computer Science; Bruce K. Willard, chief financial officer, Lincoln Laboratory; and Charlene M. Placido, assistant to the vice president and dean for research.

The committee has established an e-mail address, , and invites members of the community to offer suggestions about the search.

A version of this article appeared in the January 12, 1994 issue of MIT Tech Talk (Volume 38, Number 19).

Related Topics

More MIT News

Rich Nielsen, Volha Charnysh, Kevin Dorst, and Emily Richmond Pollock seated at a table, talking

Building a scholarly community

The SHASS Faculty Fellows Program, administered by the MIT Human Insight Collaborative, is fostering new research projects and creating space for supportive and interdisciplinary discussion.

Read full story

Globular blue and white orbs "examining" single-stranded RNA products and marking them with green checks or red x's

Why are some bacterial genes high in purines?

In certain species of bacteria, the answer lies in shielding RNA transcripts from a quality-control factor called Rho. Understanding the requirements for expressible sequences is critical for expression engineering of therapeutic agents.

Read full story